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We performed the complete screening of the CFTR gene in a group of 31 patients with COPD in order to investigate the impact of
mutations and polymorphisms in the CFTR gene. The cumulative frequency of CFTR mutations (17.74%) was significantly higher than in
our general population (P < 0.0001). The R75Q was significantly overrepresented in COPD patients (8.06%; P= 0.002). In all patients
carrying the R75Q chronic bronchitis was a dominant symptom of COPD, and all were homozygous for the V470 allele. These findings
suggest that R75Q mutation could be characteristic CFTR variant for COPD patients.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Chronic obstructive pulmonary disease (COPD); CFTR; R75Q1. Introduction
Chronic obstructive pulmonary disease (COPD) is a
condition characterized by airflow limitation that is not
fully reversible, is usually progressive and is associated
with an abnormal inflammatory response of the lung to
noxious particles or gases. COPD is composed of chronic
bronchitis (CB) and emphysema (E), which vary in propor-
tion among affected individuals and their relative contribu-
tion is difficult to define [1]. Beside environmental factors,
there is evidence to support the presence of genetic compo-
nents in the aetiology of this disease [2].
The only established genetic risk factor for COPD, so far,
is the presence of Z allele of the alpha-1-antitrypsin (AAT)
gene [3].
The CFTR gene codes for membrane protein that pri-
marily functions as a chloride channel [4]. Apart from cystic1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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E-mail address: qwert@eunet.yu (D. Radojkovic).fibrosis, several conditions have been recognized to be
associated with mutations in the CFTR gene, including:
bronchiectasis [5–8], congenital bilateral absence of vas
deferens (CBAVD) [9], chronic pancreatitis (CP) [10] and
asthma [11]. The expression of the CFTR gene in airway
cells, its multiple functions and the presence of CFTR
mutations in several lung disorders make the CFTR gene
a potential candidate for involvement in the development
of COPD.
The aim of our study was to perform complete screening
of the CFTR gene in a group of 31 patients with COPD, in
order to investigate the impact of mutations and poly-
morphisms in the CFTR gene. Additionally, we have tested
all patients for the presence of mutated Z and S alleles of
AAT gene.2. Material and methods
The group of patients consisted of 19 patients with
chronic bronchitis as a dominant symptom and 12 withed by Elsevier B.V. All rights reserved.
Table 1
CFTR genotypes in COPD patients
No. of cases CFTR gene mutation IVS8 Tn M470V genotype
1 R75Q/R75Q 7/7 V470/V470
1 L997F/R75Q 7/9 V470/V470
2 R75Q/– 7/7 V470/V470
1 F508del/– 7/9 M470/V470
1 F508del/– 5/9 M470/M470
1 G126D/– 7/9 M470/M470
1 F1052V/– 7/7 M470/V470
1 R74W/– 7/7 M470/M470
2 – /– 5/7 V470/V470
3 – /– 5/7 M470/V470
1 – /– 5/7 M470/M470
1 – /– 5/9 M470/V470
3 – /– 7/9 M470/V470
6 – /– 7/7 V470/V470
4 – /– 7/7 M470/V470
2 – /– 7/7 M470/M470
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proposed by European Respiratory Society [1]. Clinical
information was available for all patients. There were 13
females and 18 males in the group, the age range at the time
of the study was 20–83 (mean 55), and the average age of
the onset of the disease was 41.4 years. Pulmonary function
tests were performed in 29 patients. The remaining two
patients could not be assessed this way due to the severity of
the disease. The mean forced vital capacity (FVC) was
44.92F 23.46% and the mean forced expiratory volume in
one second (FEV1) was 71.13F 21.96% of predicted.
Additionally, we have tested 103 unrelated subjects from
Serbian general population for the presence of changes in
exon 3 of the CFTR gene.
DNA samples for all subjects were extracted from
whole blood by standard methods. All 27 exons and their
flanking intronic regions were amplified by PCR and
analysed by denaturing gradient gel electrophoresis
(DGGE) [12]. Any pattern variation was further investigat-
ed by automated sequencing with ALFexpress 2.0 DNA
sequencer, Pharmacia Biotech. PCR-mediated site-directed
mutagenesis was used for detection of 5T, 7T and 9T
alleles of polymorphic Tn locus in intron 8 of the CFTR
gene, as well as of M (normal), S and Z alleles of the AAT
gene [13,14]. Restriction fragments were distinguished on
10% polyacrilamide gels and the bands were visualised by
silver staining [15].
The frequency of mutations was determined by patient
counts. Differences between proportions were compared by
chi-square or Fisher’s exact test using Statistical Package for
Social Science (SPSS) program. A P value of less than 0.05
was considered to indicate statistical significance.3. Results and discussion
Mutations in the CFTR gene were identified in 9 out of
31 analyzed patients with COPD. Six different mutations
(R75Q, F508del, G126D, L997F, F1052V, R74W) were
identified on 11 (17.74%) of the 62 chromosomes, giving
a significantly higher frequency than in our general
population (P < 0.0001, 95%CI: 2.60–36.21). Distribution
of CFTR genotypes detected in COPD patients is shown
in Table 1.
One patient was homozygous for the Z allele, and one
was heterozygous carrier of Z allele of AAT gene (4.84%),
which was in concordance with frequency of Z allele in
Europe [3].
The frequency of the common CFTR gene variant, 5T
allele of IVS8 Tn locus, which modifies gene expression
by alternative splicing, was 12.9% (8/62 chromosomes),
which is significantly higher than the frequency in general
population [16] (P= 0.018; 95%CI: 1.29–7.64). Beside the
5T variant, none of the other common CFTR mutations
were more represented in comparison to the distribution in
Serbian general population. Only the gene variant R75Qstood out as the most frequent one (5/62 chromosomes,
8.06%). R75Q is a consequence of a nucleotide change
from guanine to adenine at the position 356 in CFTR gene,
which leads to an amino acid change from arginine to
glutamine. A basic polar amino acid is being substituted
with a neutral polar amino acid in exon 3, which codes for
a part of membrane spanning domain 1 (MSD1) of the
CFTR protein. Although Zielinski initially reported R75Q
as a DNA variant [17], it is possible that it represents a
mild CFTR mutation. The observed frequency of this
mutation in our general population (2/206 chromosomes)
is 0.97%. The frequency of R75Q in COPD patients was
significantly higher than in Serbian general population
(P= 0.002, 95%CI: 2.15–55.63). In all patients carrying
the R75Q, CB was a dominant symptom of COPD, they
were all non-smokers, and their FEV1 values were below
50% of predicted. They were also homozygous for the
V470 allele for which is known that in comparison to
M470 CFTR has 1.7 less instrinct chloride activity and
matures twice faster [18].
Several groups have reported R75Q in patients with DB
(1/23 patients in Italian patients with DB [6], 4/32 French
DB patients [8]), CBAVD (4/37 Slovenian CBAVD patients
[9]), CP (2/20 German CP patients [10]), and asthma (1/20
Greek asthma patients [7]). We have also investigated the
incidence of this mutation in Serbian patients with DB,
CBAVD and CP. R75Q was the most frequent, but not with
significantly higher frequency, in the group of patients with
DB (2/38 chromosomes). It was not present in any of the
patients with CP or CBAVD.
As far as we know these are the first findings observing
the increased frequency of R75Q mutation in patients with
COPD having CB as a dominant symptom. Further studies
on a larger cohort of patients, preferably in different
populations, are needed for confirming our results. Also, it
would be interesting to investigate functional consequences
of R75Q alone, as well as a possible synergistic effect of
R75Q and V470 allele.
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